Candel Therapeutics (CADL) vs Helus Pharma (HELP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Candel Therapeutics (CADL) has outperformed Helus Pharma (HELP) over the past year, gaining 74.4% versus a gain of 73.1%. Over five years, CADL leads with a -0.1% price change compared with -86.0% for HELP. Helus Pharma is the larger company by market cap ($767.9 million vs $751.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | HELP |
|---|---|---|
| Share price | $9.82 | $10.51 |
| Market cap | $751.41M | $767.86M |
| 1-day change | -0.51% | -2.32% |
| YTD return | +73.81% | +28.48% |
| 1-year return | +74.42% | +73.15% |
| 5-year return | -0.10% | -85.96% |
| EPS (TTM) | $-1.46 | $-4.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $15.15 |
| 52-week low | $4.35 | $3.76 |
| Distance from 52-week high | -29.86% | -30.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +121.49% | +278.97% |
| Average volume | 1.23M | 1.79M |
| Shares outstanding | 76.52M | 73.06M |
| Employees | 55 | 100 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Healthcare · Biotechnology · 55 employees
About Helus Pharma
HELP stock →Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.
Healthcare · Biotechnology · 100 employees
CADL vs HELP FAQ
Which is bigger, Candel Therapeutics or Helus Pharma?
Helus Pharma (HELP) is larger, with a market capitalization of $767.86M compared with $751.41M for Candel Therapeutics (CADL).
Which stock has performed better over the past year, CADL or HELP?
CADL returned +74.42% over the past 12 months, compared with +73.15% for HELP (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and Helus Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.